Navjot Chaudhary, MD, FRCSC, is a Clinical Associate Professor of Neurosurgery. She received her medical degree from McMaster University in Hamilton, Canada. Dr. Chaudhary completed her neurosurgery residency at the University of Western Ontario in London, Canada and fellowships in Spine Neurosurgery and Cyberknife Radiosurgery at Stanford University School of Medicine.

She works primarily in CyberKnife Neurosurgery at the Stanford Cancer Center, predominantly treating patients with brain and spine tumors, brain and spine arteriovenous malformations, and trigeminal neuralgia.

Her research interests include surgical outcomes. She has co-authored several papers relating to spine conditions, vascular malformations, and brain tumor management.

Clinical Focus

  • Neurosurgery
  • Spine
  • Tumors
  • Vascular Malformations
  • Trigeminal Neuralgia

Academic Appointments

Administrative Appointments

  • Clinical Assistant Professor, Stanford Healthcare (2015 - Present)

Professional Education

  • Medical Education:McMaster University Michael G DeGroote School of Medicine Registrar (2007) Canada
  • Residency:University of Western Ontario (2013) Canada
  • Fellowship:University of Western Ontario (2012) Canada
  • Internship:University of Western Ontario (2008) Canada
  • Board Certification: Neurosurgery, Royal College of Physicians and Surgeons of Canada


All Publications

  • Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment. Neuro-oncology Liu, T. T., Achrol, A. S., Mitchell, L. A., Rodriguez, S. A., Feroze, A., Kim, C., Chaudhary, N., Gevaert, O., Stuart, J. M., Harsh, G. R., Chang, S. D., Rubin, D. L. 2016


    In previous clinical trials, antiangiogenic therapies such as bevacizumab did not show efficacy in patients with newly diagnosed glioblastoma (GBM). This may be a result of the heterogeneity of GBM, which has a variety of imaging-based phenotypes and gene expression patterns. In this study, we sought to identify a phenotypic subtype of GBM patients who have distinct tumor-image features and molecular activities and who may benefit from antiangiogenic therapies.Quantitative image features characterizing subregions of tumors and the whole tumor were extracted from preoperative and pretherapy perfusion magnetic resonance (MR) images of 117 GBM patients in 2 independent cohorts. Unsupervised consensus clustering was performed to identify robust clusters of GBM in each cohort. Cox survival and gene set enrichment analyses were conducted to characterize the clinical significance and molecular pathway activities of the clusters. The differential treatment efficacy of antiangiogenic therapy between the clusters was evaluated.A subgroup of patients with elevated perfusion features was identified and was significantly associated with poor patient survival after accounting for other clinical covariates (P values <.01; hazard ratios > 3) consistently found in both cohorts. Angiogenesis and hypoxia pathways were enriched in this subgroup of patients, suggesting the potential efficacy of antiangiogenic therapy. Patients of the angiogenic subgroups pooled from both cohorts, who had chemotherapy information available, had significantly longer survival when treated with antiangiogenic therapy (log-rank P=.022).Our findings suggest that an angiogenic subtype of GBM patients may benefit from antiangiogenic therapy with improved overall survival.

    View details for DOI 10.1093/neuonc/now270

    View details for PubMedID 28007759

  • Evidence for use of Teriparatide in Spinal Fusion Surgery in Osteoporotic Patients. World neurosurgery Chaudhary, N., Lee, J. S., Wu, J. Y., Tharin, S. 2016


    Osteoporosis is defined as a bone mineral density (BMD) less than 2.5 standard deviations below the mean BMD at peak bone mass, or the presence of a fragility fracture. In the setting of osteoporosis, early hardware loosening is thought to cause decreased spinal fusion rates. The two mainstays of osteoporosis treatment are bisphosphonates and Teriparatide. Teriparatide, a form of synthetic parathyroid hormone (PTH), is an anabolic agent that increases osteoblast activity and, thereby, bone mass. Preclinical studies in animal models show that Teriparatide increases spinal fusion rates. Early clinical studies show that teriparatide both increases spinal fusion rates and decreases hardware loosening in the setting of postmenopausal osteoporosis. Ongoing additional trials will help formulate preoperative screening recommendations, determine the optimal duration of pre- and post-operative Teriparatide treatment, and investigate its utility in men.

    View details for DOI 10.1016/j.wneu.2016.11.135

    View details for PubMedID 27923758

  • Stereotactic radiosurgery for metastasis to the craniovertebral junction preserves spine stability and offers symptomatic relief JOURNAL OF NEUROSURGERY-SPINE Azad, T. D., Esparza, R., Chaudhary, N., Chang, S. D. 2016; 24 (2): 241-247
  • Stereotactic radiosurgery for metastasis to the craniovertebral junction preserves spine stability and offers symptomatic relief. Journal of neurosurgery. Spine Azad, T. D., Esparza, R., Chaudhary, N., Chang, S. D. 2015: 1-7


    OBJECT Metastatic disease to the craniovertebral junction (CVJ) is rare but presents unique management challenges. To date, studies on using stereotactic radiosurgery (SRS) for CVJ metastases have been limited to case reports and small case series. The aim of this analysis was to evaluate the utility of SRS in the management of these secondary lesions. METHODS Clinical and radiological information from the charts of 25 patients with metastatic disease of the CVJ who were treated with SRS between 2005 and 2013 at the Stanford CyberKnife Center were retrospectively reviewed. RESULTS Seven male and 18 female patients with a median age of 58 years (range 34-94 years) were identified. The most common primary tumors were breast cancer (n = 5) and non-small cell lung cancer (n = 5), and the most frequent symptom was neck pain (n = 17). The average tumor volume treated was 15.9 cm(3) (range 0.16-54.1 cm(3)), with a mean marginal radiation dose of 20.3 Gy (range 15-25.5 Gy). The median follow-up was 18 months (range 1-81 months), though 1 patient was lost to follow-up. SRS provided radiographic tumor stability in over 80% of patients, offered pain alleviation in nearly two-thirds of patients, and produced no serious complications. Moreover, SRS preserved spinal stability in all but 1 patient, in whom pre-SRS stability was established. There was no evidence of radiation toxicity in the patient population. Median survival was 28 months (range 2-81 months), with survival of 13.3% at 5 years. CONCLUSIONS In the absence of unstable pathological fracture and spinal cord compression, metastatic tumors of the CVJ can be safely and effectively treated with SRS. This treatment option offers palliative pain relief and can halt tumor progression with only a low risk of complications or spinal instability.

    View details for PubMedID 26516666

  • A Modified Retromaxillary Approach to the Infratemporal Fossa: Three Case Studies JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY Woodford, R., Chaudhary, N., Wolf, A., Lownie, S., Armstrong, J. E. 2015; 73 (4): 769-780


    The infratemporal fossa (ITF) is an anatomically complex region with multiple neural and vascular structures entering and exiting through foramina in the skull base. The main obstacles to approaching the ITF are the zygomatic arch, the parotid gland, the facial nerve, and the ascending ramus AND condylar head of the mandible. Different surgical approaches to the ITF exist and the best approach should provide optimal visibility, minimal impairment of temporomandibular joint function, and preservation of motor and sensory nerve integrity. This report describes a modified Obwegeser retromaxillary approach to access lesions within the ITF. A multidisciplinary team was involved, which included an oral and maxillofacial surgery team, a neurosurgery team, and an otolaryngology team. Three patients with large skull base lesions, including an aneurysmal bone cyst, a giant cell tumor of the bone, and an invasive melanoma, underwent resection using this approach and were followed postoperatively. Excellent exposure of the floor of the middle cranial fossa and ITF was achieved with this approach. Functional status remained unchanged with respect to mastication, speech, swallowing, and cosmesis. Given the severity of the patients' conditions and extent of involvement of the skull base, outcomes were favorable, with minimal morbidity. This experience suggests that this approach provides safe access to an anatomically complex region and lessens challenges associated with more conventional approaches.

    View details for DOI 10.1016/j.joms.2014.10.025

    View details for Web of Science ID 000351240100034

    View details for PubMedID 25631866

  • Familial syndromes associated with intracranial tumours: a review CHILDS NERVOUS SYSTEM Ranger, A. M., Patel, Y. K., Chaudhary, N., Anantha, R. V. 2014; 30 (1): 47-64


    Most cancers of the central nervous system (CNS) occur sporadically in the absence of any known underlying familial disorder or multi-systemic syndrome. Several syndromes are associated with CNS malignancies, however, and their recognition has significant implications for patient management and prognosis. Patients with syndrome-associated CNS malignancies often have multiple tumours (either confined to one region or distributed throughout the body), with similar or different histology.This review examines syndromes that are strongly associated with CNS cancers: the phakomatosis syndromes, familial syndromes such as Li-Fraumeni and familial polyposis syndromes and dyschondroplasia.

    View details for DOI 10.1007/s00381-013-2309-z

    View details for Web of Science ID 000329624100006

    View details for PubMedID 24193148